BOSTON, June 6, 2019-- Third Rock Ventures, LLC announced today the closing of Third Rock Ventures V, LP (“Fund V”), raising $770 million in an oversubscribed fund. With Fund V, the firm will continue to execute on its strategy of discovering, launching and building innovative life sciences companies that have the potential to transform the lives of patients and their families. Since its inception in 2007, Third Rock has raised $2.7 billion to create companies focused in many different areas of high unmet medical need including cancer, neurological disorders, rare genetic diseases, immune disorders, and cardiovascular diseases.